Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes
Sandrine Levet, Julie Medina, Julie Joanou, Amandine Demolder, Nelly Queruel, Kevin Réant, Matthieu Normand, Marine Seffals, Julie Dimier, Raphaële Germi, Thomas Piofczyk, Jacques Portoukalian, Jean-Louis Touraine, Hervé Perron
Sandrine Levet, Julie Medina, Julie Joanou, Amandine Demolder, Nelly Queruel, Kevin Réant, Matthieu Normand, Marine Seffals, Julie Dimier, Raphaële Germi, Thomas Piofczyk, Jacques Portoukalian, Jean-Louis Touraine, Hervé Perron
View: Text | PDF
Research Article Endocrinology

An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes

  • Text
  • PDF
Abstract

Human endogenous retroviruses (HERVs), remnants of ancestral viral genomic insertions, are known to represent 8% of the human genome and are associated with several pathologies. In particular, the envelope protein of HERV-W family (HERV-W-Env) has been involved in multiple sclerosis pathogenesis. Investigations to detect HERV-W-Env in a few other autoimmune diseases were negative, except in type-1 diabetes (T1D). In patients suffering from T1D, HERV-W-Env protein was detected in 70% of sera, and its corresponding RNA was detected in 57% of peripheral blood mononuclear cells. While studies on human Langerhans islets evidenced the inhibition of insulin secretion by HERV-W-Env, this endogenous protein was found to be expressed by acinar cells in 75% of human T1D pancreata. An extensive immunohistological analysis further revealed a significant correlation between HERV-W-Env expression and macrophage infiltrates in the exocrine part of human pancreata. Such findings were corroborated by in vivo studies on transgenic mice expressing HERV-W-env gene, which displayed hyperglycemia and decreased levels of insulin, along with immune cell infiltrates in their pancreas. Altogether, these results strongly suggest an involvement of HERV-W-Env in T1D pathogenesis. They also provide potentially novel therapeutic perspectives, since unveiling a pathogenic target in T1D.

Authors

Sandrine Levet, Julie Medina, Julie Joanou, Amandine Demolder, Nelly Queruel, Kevin Réant, Matthieu Normand, Marine Seffals, Julie Dimier, Raphaële Germi, Thomas Piofczyk, Jacques Portoukalian, Jean-Louis Touraine, Hervé Perron

×

Figure 3

Proinflammatory features associated with HERV-W-Env expression within the pancreas.

Options: View larger image (or click on image) Download as PowerPoint
Proinflammatory features associated with HERV-W-Env expression within th...
(A) Pancreas of nPOD T1D cases 6036 and 6054 were immunostained with GN_mAb_Env03 (upper panels), and adjacent slides were immunostained with anti-CD3 (orange) and anti-CD68 (red) (lower panels). Lower panels display the same areas as upper panels. Scale bars: 100 μm. (B–G) Percentages of CD68+ (B) and CD3+ (D) cells in the exocrine pancreas are presented for controls (n = 19) and T1D patients (n = 20) and as a function of HERV-W-Env+ area (C and E, respectively) (Figure 1C). The relationship between CD3+ and CD68+ cells for each T1D donor is presented in F, which allowed to determine 3 groups: (i) CD3low/CD68low, (ii) CD3high/CD68low, and (iii) CD68high/CD3low. Based on this plot, the cutoff for CD3+ cells is set at 0.065%, and for CD68+ cells, it is set at 0.1%. The HERV-W-Env+ area presented in Figure 1C was reanalyzed in these 3 groups and was presented as mean for each individual and mean ± SEM for each group (G). Significance determined by Mann Whitney U test (B and D), by Spearman test (C), and by Kruskal-Wallis test followed by Dunn multiple comparison test (G). *P < 0.05, **P < 0.01, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts